OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.

Trial Profile

OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Aflibercept (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms GERCOR VELVET; VELVET
  • Most Recent Events

    • 05 Apr 2017 Results of a biomarker analysis presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 28 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 02 Dec 2016 Results of a biomarker analysis presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top